ES2928684T3 - Agente terapéutico para la fibrosis - Google Patents
Agente terapéutico para la fibrosis Download PDFInfo
- Publication number
- ES2928684T3 ES2928684T3 ES16814513T ES16814513T ES2928684T3 ES 2928684 T3 ES2928684 T3 ES 2928684T3 ES 16814513 T ES16814513 T ES 16814513T ES 16814513 T ES16814513 T ES 16814513T ES 2928684 T3 ES2928684 T3 ES 2928684T3
- Authority
- ES
- Spain
- Prior art keywords
- fibrosis
- amino
- present
- acid
- interstitial pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2928684T3 true ES2928684T3 (es) | 2022-11-21 |
Family
ID=57585165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16814513T Active ES2928684T3 (es) | 2015-06-25 | 2016-06-24 | Agente terapéutico para la fibrosis |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (https=) |
| EP (2) | EP3973962A1 (https=) |
| JP (3) | JP6974167B2 (https=) |
| KR (1) | KR102647942B1 (https=) |
| CN (2) | CN112716952A (https=) |
| AU (1) | AU2016284531B2 (https=) |
| BR (1) | BR112017028137B1 (https=) |
| CA (1) | CA2990791A1 (https=) |
| DK (1) | DK3315131T3 (https=) |
| ES (1) | ES2928684T3 (https=) |
| HU (1) | HUE060732T2 (https=) |
| MA (1) | MA42266A (https=) |
| MX (2) | MX381792B (https=) |
| MY (1) | MY191219A (https=) |
| PH (1) | PH12017502322B1 (https=) |
| PL (1) | PL3315131T3 (https=) |
| PT (1) | PT3315131T (https=) |
| RU (1) | RU2729630C2 (https=) |
| SG (2) | SG11201709260TA (https=) |
| WO (1) | WO2016208744A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| MA42266A (fr) * | 2015-06-25 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Agent thérapeutique contre la fibrose |
| HUE068810T2 (hu) | 2017-02-15 | 2025-01-28 | Taiho Pharmaceutical Co Ltd | Gyógyászati készítmény |
| MA50251A (fr) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co Ltd | Agent antitumoral et potentialisateur d'effet antitumoral |
| US20210369739A1 (en) | 2018-09-18 | 2021-12-02 | Taiho Pharmaceutical Co., Ltd. | Combination therapy of acylthiourea compound and abiraterone |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69939586D1 (de) | 1998-04-28 | 2008-10-30 | Toshikazu Nakamura | Inhibitoren für die gefässneubildung |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| WO2007005668A2 (en) | 2005-06-30 | 2007-01-11 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| CN101360748B (zh) * | 2005-11-30 | 2012-05-30 | 沃泰克斯药物股份有限公司 | c-MET抑制剂及其应用 |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| ATE523508T1 (de) | 2007-10-25 | 2011-09-15 | Astrazeneca Ab | Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate |
| KR101414931B1 (ko) * | 2008-04-10 | 2014-07-04 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물 또는 그 염 및 그 용도 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| EA025304B1 (ru) * | 2010-02-03 | 2016-12-30 | Инсайт Холдингс Корпорейшн | ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| MA42266A (fr) * | 2015-06-25 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Agent thérapeutique contre la fibrose |
-
2016
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2928684T3 (es) | Agente terapéutico para la fibrosis | |
| TW201827056A (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| BR112020018601A2 (pt) | Regime de dosagem de modulador de montagem de capsídeo | |
| ES2989178T3 (es) | Inhibidores de la producción de prostaglandina D2 como agentes preventivos y terapéuticos para la sarcopenia | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| ES2970909T3 (es) | Composición farmacéutica para administración nasal que comprende rifampicinas para el tratamiento de la demencia | |
| US11197912B2 (en) | Prevention and treatment of viral infection and viral infection-induced organ failure | |
| ES2951575T3 (es) | Imeglimina para la prevención y/o tratamiento del carcinoma hepatocelular | |
| JPWO2017217071A1 (ja) | セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤 | |
| JP7854206B2 (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| EP3866775B1 (en) | Cysteamine for use in the treatment of lung diseases | |
| HK40046439A (en) | Therapeutic agent for fibrosis | |
| KR20250129611A (ko) | 약학 조합물 및 이의 용도 | |
| KR20250092218A (ko) | 인슐린 저항성 및 연관 장애의 치료 방법 |